These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 7954426

  • 1. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI.
    Cancer Res; 1994 Nov 15; 54(22):5937-46. PubMed ID: 7954426
    [Abstract] [Full Text] [Related]

  • 2. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP, Goodwin DA, Meares CF, Song C, Osen M, Hays M.
    J Nucl Med; 2001 Apr 15; 42(4):670-8. PubMed ID: 11337558
    [Abstract] [Full Text] [Related]

  • 3. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 4. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA, Meares CF, Osen M.
    J Nucl Med; 1998 Oct 01; 39(10):1813-8. PubMed ID: 9776294
    [Abstract] [Full Text] [Related]

  • 5. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A.
    Nucl Med Biol; 2005 Oct 01; 32(7):741-7. PubMed ID: 16243650
    [Abstract] [Full Text] [Related]

  • 6. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998 Oct 01; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH.
    J Nucl Med; 1994 May 01; 35(5):882-9. PubMed ID: 8176477
    [Abstract] [Full Text] [Related]

  • 8. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr 01; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 9. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [Abstract] [Full Text] [Related]

  • 10. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 11. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 12. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2005 Mar 01; 46(3):495-501. PubMed ID: 15750164
    [Abstract] [Full Text] [Related]

  • 13. Interferon enhancement of radioimmunotherapy for colon carcinoma.
    Kuhn JA, Beatty BG, Wong JY, Esteban JM, Wanek PM, Wall F, Buras RR, Williams LE, Beatty JD.
    Cancer Res; 1991 May 01; 51(9):2335-9. PubMed ID: 1901760
    [Abstract] [Full Text] [Related]

  • 14. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.
    J Nucl Med; 1997 Dec 01; 38(12):1944-50. PubMed ID: 9430475
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 16. Specific radioimmunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice.
    Anderson-Berg WT, Squire RA, Strand M.
    Cancer Res; 1987 Apr 01; 47(7):1905-12. PubMed ID: 3469024
    [Abstract] [Full Text] [Related]

  • 17. Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer.
    Ito T, Qiu H, Collins JA, Brill AB, Johnson DK, Griffin TW.
    Cancer Res; 1991 Jan 01; 51(1):255-60. PubMed ID: 1988087
    [Abstract] [Full Text] [Related]

  • 18. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ.
    Cancer Res; 1993 Jul 01; 53(13):3022-7. PubMed ID: 8319209
    [Abstract] [Full Text] [Related]

  • 19. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N, Saga T, Sakahara H, Yao Z, Nakamoto Y, Zhang M, Kuroki M, Matsuoka Y, Iida Y, Konishi J.
    J Nucl Med; 1999 Apr 01; 40(4):685-92. PubMed ID: 10210230
    [Abstract] [Full Text] [Related]

  • 20. Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice.
    Morton BA, Beatty BG, Mison AP, Wanek PM, Beatty JD.
    Cancer Res; 1990 Feb 01; 50(3 Suppl):1008s-1010s. PubMed ID: 2297712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.